Brief: Cumberland Pharmaceuticals to acquire Vibativ

Cumberland Pharmaceuticals

06/11/2018 13:42

Nov 6 (Reuters) - Cumberland Pharmaceuticals Inc  CPIX.O :
    * CUMBERLAND PHARMACEUTICALS TO ACQUIRE VIBATIV
    * CUMBERLAND PHARMACEUTICALS INC - FINANCIAL TERMS INCLUDE A
$20
MILLION PAYMENT TO THERAVANCE BIOPHARMA UPON CLOSING
    * CUMBERLAND PHARMACEUTICALS INC - FINANCIAL TERMS INCLUDE A
$20
MILLION PAYMENT TO THERAVANCE BIOPHARMA UPON CLOSING
    * CUMBERLAND PHARMACEUTICALS INC - CUMBERLAND EXPECTS THAT
ADDITION OF VIBATIV WILL BE ACCRETIVE TO COMPANY'S EARNINGS.
    * CUMBERLAND PHARMACEUTICALS INC - TERMS ALSO INCLUDE A $5
MILLION
ADDITIONAL PAYMENT IN EARLY 2019
    * CUMBERLAND PHARMACEUTICALS - TERMS HAVE $5 MILLION
ADDITIONAL
PAYMENT IN EARLY 2019, AND TIERED ROYALTIES OF UP TO 20% ON
FUTURE US NET PRODUCT SALES
    * CUMBERLAND PHARMACEUTICALS INC - ENTERED DEFINITIVE
AGREEMENT TO
ACQUIRE VIBATIV FROM THERAVANCE BIOPHARMA

Source text for Eikon:  ID:nPnbCVfTwa 
Further company coverage:  CPIX.O 

 ((Briefs@thomsonreuters.com;))